| Gene Name | Gene Symbol | Locus ID | References |
| CD44 antigen (homing function and Indian blood group system) | CD44 | 960 | 6 |
| cyclin-dependent kinase inhibitor 1B (p27, Kip1) | CDKN1B | 1027 | 3 |
| cadherin 1, type 1, E-cadherin (epithelial) | CDH1 | 999 | 9 |
| beta-transducin repeat containing | BTRC | 8945 | 1 |
| insulin-like growth factor binding protein 3 | IGFBP3 | 3486 | 1 |
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | SMARCA4 | 6597 | 1 |
| NK3 transcription factor homolog A (Drosophila) | NKX3A | 4824 | 2 |
| v-Ha-ras Harvey rat sarcoma viral oncogene homolog | HRAS | 3265 | 14 |
| neurotrophic tyrosine kinase, receptor, type 1 | NTRK1 | 4914 | 1 |
| tumor protein p53 (Li-Fraumeni syndrome) | TP53 | 7157 | 53 |
| phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | PTEN | 5728 | 18 |
| hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | HSD3B2 | 3284 | 2 |
| core promoter element binding protein | COPEB | 1316 | 1 |
| adenomatosis polyposis coli | APC | 324 | 2 |
| vang-like 2 (van gogh, Drosophila) | VANGL2 | 57216 | 1 |
| elaC homolog 2 (E. coli) | ELAC2 | 60528 | 9 |
| cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | CDKN2A | 1029 | 14 |
| gene differentially expressed in prostate | GDEP | 118425 | 2 |
| arginine-rich, mutated in early stage tumors | ARMET | 7873 | 1 |
| ring finger protein 14 | RNF14 | 9604 | 1 |
| cyclin-dependent kinase inhibitor 1A (p21, Cip1) | CDKN1A | 1026 | 3 |
| predisposing for prostate cancer | PCAP | 7834 | 3 |
| ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) | RNASEL | 6041 | 3 |
| breast cancer 2, early onset | BRCA2 | 675 | 8 |
| homeo box A13 | HOXA13 | 3209 | 1 |
| androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) | AR | 367 | 91 |
| MAD, mothers against decapentaplegic homolog 2 (Drosophila) | MADH2 | 4087 | 1 |
| non-metastatic cells 1, protein (NM23A) expressed in | NME1 | 4830 | 1 |
| hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | HSD3B1 | 3283 | 1 |
| breast cancer 1, early onset | BRCA1 | 672 | 8 |
| catenin (cadherin-associated protein), alpha 1 (102kD) | CTNNA1 | 1495 | 2 |
| cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6 | CYP2D6 | 1565 | 1 |
| protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) | PTPN13 | 5783 | 1 |
| CCCTC-binding factor (zinc finger protein) | CTCF | 10664 | 2 |
| MAD1 mitotic arrest deficient-like 1 (yeast) | MAD1L1 | 8379 | 1 |
| kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)) | KAI1 | 3732 | 4 |
| cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 | CYP3A4 | 1576 | 1 |
| transmembrane protease, serine 2 | TMPRSS2 | 7113 | 1 |
| polymerase (DNA directed), beta | POLB | 5423 | 1 |
| retinoblastoma 1 (including osteosarcoma) | RB1 | 5925 | 5 |
| steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | SRD5A2 | 6716 | 13 |
| early growth response 1 | EGR1 | 1958 | 1 |
| catenin (cadherin-associated protein), beta 1 (88kD) | CTNNB1 | 1499 | 5 |
| 8-oxoguanine DNA glycosylase | OGG1 | 4968 | 1 |
| mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) | MSH2 | 4436 | 1 |
| MAX interacting protein 1 | MXI1 | 4601 | 4 |
| ataxia telangiectasia mutated (includes complementation groups A, C and D) | ATM | 472 | 1 |
